CONITEC takes credit for Brazilian Herceptin court case fall
This article was originally published in Scrip
A drop in the number of court cases brought by patients against Brazilian health authorities to access Roche's breast cancer drug Herceptin (trastuzumab) could be an early sign that the new health technology appraisal body, CONITEC, is doing a good job, it told Scrip.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.